Fake Mounjaro to unapproved retatrutide: Inside India's booming weight-loss drug black market

India’s informal weight-loss market was selling several different products. These included fake versions of Eli Lilly’s Mounjaro, heavily discounted injections, generic semaglutide brands, and experimental retatrutide. The products reached buyers through IndiaMART, Telegram, WhatsApp, and other unofficial channels.

Investigators found counterfeit Mounjaro during a raid in Gurugram. The operation used injector pens, syringes, labels, and packaging carrying Lilly branding. Tests by Eli Lilly found some doses contained 30% or less of the labelled amount of tirzepatide. Retatrutide was also recovered, although it has not been approved by any regulator.

The article shows two separate dangers. Counterfeit medicines falsely imitate approved products. Unauthorised medicines have not completed the regulatory process for sale. India also has nearly three dozen generic semaglutide brands after the relevant patent expired, but legitimate generics are different from unapproved or falsified products.

Counterfeit Mounjaro is not genuine Eli Lilly medicine. It is a product made or packaged to imitate Mounjaro, including its injector pens, labels, and branding. The risk is that buyers may believe they are receiving a regulated medicine when the contents do not match the label.

The investigation began when a Haryana drug control officer saw Mounjaro advertised at about 20% below its usual monthly retail price of ₹13,125. Investigators traced a seller to a Gurugram apartment containing pens, syringes, packaging, and peptide vials. Eli Lilly tested products seized there and identified them as counterfeit. Some doses contained 30% or less of the labelled concentration of tirzepatide, Mounjaro’s active ingredient.

That testing compared the medicine’s actual contents with its stated strength. The result showed that convincing packaging could hide major differences in dose. A low dose may fail to deliver the expected treatment, while unknown contents create additional safety concerns.

The article describes a rapidly expanding market but does not provide a total sales value or patient count. It reports that expensive branded obesity medicines created demand for cheaper alternatives. It also identifies an underground supply network using online marketplaces, Telegram, WhatsApp, doctors, wellness centres, and beauty clinics.

The clearest measure of legitimate competition is semaglutide. After Novo Nordisk’s patent for the active ingredient expired, nearly three dozen generic brands entered India. These products reportedly include tablets, vials, and injectable forms. The same investigation found counterfeit Mounjaro and listings for retatrutide, which is still experimental.

This means market size cannot be reduced to one number. Legitimate generic competition is growing, while illicit sales are harder to measure because they occur outside normal distribution systems. The article suggests both markets are being driven by demand for more affordable weight-loss treatment, but it does not quantify their overall scale.

Injectable medicines must contain the right substance, strength, and sterile ingredients. A counterfeit product can fail on any of these points. If it contains much less active ingredient than claimed, it may not produce the expected treatment effect. If it contains a different substance, the reaction may be unpredictable.

The article provides a concrete warning. Eli Lilly found that some seized counterfeit Mounjaro doses contained 30% or less of the labelled tirzepatide concentration. The fake products were packaged to resemble genuine pens. More generally, contaminated injections can introduce harmful particles or microorganisms directly into the body, potentially causing serious local or systemic infection.

The outcome depends on what the product contains and how it was made. Patients may experience treatment failure, unexpected side effects, or infection. The article does not report specific patient injuries, so those consequences are established medical risks rather than documented outcomes in this investigation.

Patients are seeking cheaper weight-loss treatment because branded obesity medicines can be expensive. The article says this price pressure has helped create demand for alternatives. In the investigation, Mounjaro was advertised at about 20% below its usual monthly retail price of ₹13,125, making the offer especially attractive.

Access is another factor. Sellers use IndiaMART, TradeIndia, Telegram, WhatsApp, and other informal channels. These routes can connect consumers with products without the checks normally applied through authorised suppliers. India’s large pharmaceutical manufacturing ecosystem also gives counterfeiters access to ingredients, packaging, and other supplies.

The lower price and easy access do not guarantee safety. Buyers may encounter counterfeit Mounjaro, understrength injections, or retatrutide, which has no approval for human sale. The article shows how demand, affordability, and informal online distribution can expand together while making verification more difficult.

Retatrutide is an investigational obesity medicine being developed by Eli Lilly. It remains under clinical development, meaning researchers are still studying its benefits, risks, dose, and appropriate use. It is not the same as an approved medicine that doctors can routinely prescribe and pharmacies can legally sell.

Bloomberg reported that investigators recovered retatrutide during the Gurugram raid. Unofficial distributors had also approached doctors, wellness centres, and beauty clinics in Mumbai. Listings appeared on IndiaMART and TradeIndia. Lilly told Bloomberg that retatrutide is available through its clinical trials and has not been approved by any regulator anywhere in the world.

Clinical-trial access is controlled and limited to approved research settings. Selling the drug outside those settings bypasses evidence collection, medical oversight, quality controls, and regulatory review. Until approval occurs, no one can legally sell retatrutide for human use, even if advertisements claim it is effective or authentic.

Clinical trials test how well a medicine works and what risks it carries in defined groups of people. Regulators review that evidence, along with manufacturing and quality information, before granting approval. Approval determines whether a product can legally be sold for a particular use. It does not automatically cover an experimental medicine.

Patents are different. They give the patent holder time-limited protection over an invention. After Novo Nordisk’s patent for semaglutide’s active ingredient expired in India, generic manufacturers entered the market. The article reports nearly three dozen brands, including tablets, vials, and injections. Those products still need to meet applicable quality and regulatory requirements.

This system separates legitimate competition from counterfeiting. Approved manufacturers can produce authorised medicines under regulated conditions. Unofficial sellers cannot legally market an investigational product such as retatrutide or imitate Mounjaro. A patent expiry may open competition, but it does not make every product safe or lawful.